Investigation of secondary hyperparathyroidism and its contributing factors in hemodialysis patients: A cross-sectional study
Mahdieh Jamshidi, Golamreza Bazmandegan, Zahra Kamiab, Mohammad Rasool Dehghani Firouzabadi, Mohammad Ali Zakeri, Alaa Hamza Hermis, Saadya Hadi Humade, Mahmood KahnoojiBACKGROUND:
Hemodialysis may lead to changes in serum levels of important parameters such as calcium and phosphorus, which can also affect the level of parathyroid hormone. The present study aimed to determine the prevalence and some causes of secondary hyperparathyroidism (SHPT) in hemodialysis patients.
MATERIALS AND METHODS:
The population of this descriptive-cross-sectional study included 60 hemodialysis patients admitted to the hospital in the southeast of Iran, all of whom were enrolled in the study through convenience sampling. Sociodemographic characteristics, hematologic and biochemical indices, and serum parathyroid hormone (PTH) levels were examined. A PTH hormone cut-off level of 300 picograms per deciliter was considered. Data were analyzed using an independent
RESULT:
The mean age of the participants was 53.16 ± 8.60 years. Among these, 34 (56.7%) were diagnosed with SHPT, and 58 (96.7%) had underlying diseases. Additionally, 17 (28.3%) had abnormal calcium levels, 40 (66.7%) had abnormal phosphorus levels, four (6.7%) had abnormal alkaline phosphatase (ALP), and 19 (31.7%) had abnormal Ca × P. The mean levels of PTH (
CONCLUSION:
Based on the results of this study, the higher levels of ALP in hemodialysis patients with SHPT suggest that regular monitoring of laboratory tests, particularly alkaline phosphatase, can be beneficial in the follow-up of these patients.